Feprazone

Feprazone
Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	M02AA16 ( WHO );
Identifiers
	IUPAC name 4-(3-methylbut-2-enyl)-1,2-di(phenyl)pyrazolidine-3,5-dione;
CAS Number	30748-29-9 ;
PubChem CID	35455 ;
ChemSpider	32612 ;
UNII	7BVX6J0CGR ;
KEGG	D01305 ;
CompTox Dashboard (EPA)	DTXSID3023051 ;
ECHA InfoCard	100.045.735
Chemical and physical data
Formula	C20H20N2O2
Molar mass	320.392 g·mol−1
3D model (JSmol)	Interactive image ;
	SMILES O=C2N(c1ccccc1)N(C(=O)C2C\C=C(/C)C)c3ccccc3;
	InChI InChI=1S/C20H20N2O2/c1-15(2)13-14-18-19(23)21(16-9-5-3-6-10-16)22(20(18)24)17-11-7-4-8-12-17/h3-13,18H,14H2,1-2H3 ; Key:RBBWCVQDXDFISW-UHFFFAOYSA-N ;
	(verify)

Last updated October 27, 2023

Feprazone (or prenazone) is a drug used for joint and muscular pain.^[1]

It is an analog of phenylbutazone but instead of a n-butyl group it is prenylated.

Related Research Articles

2C-T-2 is a psychedelic and entactogenic phenethylamine of the 2C family. It was first synthesized in 1981 by Alexander Shulgin, and rated by him as one of the "magical half-dozen" most important psychedelic phenethylamine compounds. The drug has structural and pharmacodynamic properties similar to those of 2C-T-7.

ATC code M01Anti-inflammatory and antirheumatic products is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products. Subgroup M01 is part of the anatomical group M Musculo-skeletal system.

<span class="mw-page-title-main">Nefiracetam</span> Chemical compound

Nefiracetam is a nootropic drug of the racetam family. Preliminary research suggests that it may possess certain antidementia properties in rats.

Toxicogenomics is a subdiscipline of pharmacology that deals with the collection, interpretation, and storage of information about gene and protein activity within a particular cell or tissue of an organism in response to exposure to toxic substances. Toxicogenomics combines toxicology with genomics or other high-throughput molecular profiling technologies such as transcriptomics, proteomics and metabolomics. Toxicogenomics endeavors to elucidate the molecular mechanisms evolved in the expression of toxicity, and to derive molecular expression patterns that predict toxicity or the genetic susceptibility to it.

<span class="mw-page-title-main">5-MeO-DPT</span> Chemical compound

5-MeO-DPT, is a psychedelic and entheogenic designer drug.

<span class="mw-page-title-main">Amperozide</span> Chemical compound

Amperozide is an atypical antipsychotic of the diphenylbutylpiperazine class which acts as an antagonist at the 5-HT_2A receptor. It does not block dopamine receptors as with most antipsychotic drugs, but does inhibit dopamine release, and alters the firing pattern of dopaminergic neurons. It was investigated for the treatment of schizophrenia in humans, but never adopted clinically. Its main use is instead in veterinary medicine, primarily in intensively farmed pigs, for decreasing aggression and stress and thereby increasing feeding and productivity.

PRC200-SS is an experimental drug of the triple reuptake inhibitor class that was investigated by the Mayo Clinic.

25-C-NBOH is a derivative of the phenethylamine derived hallucinogen 2C-C which has been sold as a designer drug. It has similar serotonin receptor affinity to the better-known compound 25C-NBOMe.

<span class="mw-page-title-main">Diphenidine</span> Chemical compound

Diphenidine is a dissociative anesthetic that has been sold as a designer drug. The synthesis of diphenidine was first reported in 1924, and employed a Bruylants reaction analogous to the one that would later be used to discover phencyclidine in 1956. Shortly after the 2013 UK ban on arylcyclohexylamines, diphenidine and the related compound methoxphenidine became available on the grey market. Anecdotal reports describe high doses of diphenidine producing "bizarre somatosensory phenomena and transient anterograde amnesia." Diphenidine and related diarylethylamines have been studied in vitro as treatments for neurotoxic injury and are antagonists of the NMDA receptor. In dogs diphenidine exhibits greater antitussive potency than codeine phosphate.

<span class="mw-page-title-main">THJ-2201</span> Synthetic cannabinoid

THJ-2201 is an indazole-based synthetic cannabinoid that presumably acts as a potent agonist of the CB₁ receptor and has been sold online as a designer drug.

<span class="mw-page-title-main">Furanylfentanyl</span> Opioid analgesic

Furanylfentanyl (Fu-F) is an opioid analgesic that is an analog of fentanyl and has been sold as a designer drug. It has an ED₅₀ value of 0.02 mg/kg in mice. This makes it approximately one fifth as potent as fentanyl.

<span class="mw-page-title-main">MDMB-CHMICA</span> Chemical compound

MDMB-CHMICA is an indole-based synthetic cannabinoid that is a potent agonist of the CB₁ receptor and has been sold online as a designer drug. While MDMB-CHMICA was initially sold under the name "MMB-CHMINACA", the compound corresponding to this code name (i.e. the isopropyl instead of t-butyl analogue of MDMB-CHMINACA) has been identified on the designer drug market in 2015 as AMB-CHMINACA.

FDU-PB-22 is a derivative of JWH-018 that is presumed to be a potent agonist of the CB₁ receptor, and has been sold online as a designer drug.

FUB-PB-22 (QUFUBIC) is an indole-based synthetic cannabinoid that is a potent agonist of the CB₁ receptor and has been sold online as a designer drug.

FDU-NNE1 (also known as FDU-NNEI and FDU-MN-24) is an indole-based synthetic cannabinoid that is presumed to be a potent agonist of the CB₁ receptor and has been sold online as a designer drug. Given the known metabolic liberation (and presence as an impurity) of amantadine in the related compound APINACA, it is suspected that metabolic hydrolysis of the amide group of FDU-NNE1 will release 1-naphthylamine, a known carcinogen.

<span class="mw-page-title-main">4'-Methoxy-α-pyrrolidinopentiophenone</span> Stimulant drug

4'-Methoxy-α-pyrrolidinopentiophenone is a stimulant drug of the cathinone class that has been sold online as a designer drug.

<span class="mw-page-title-main">Mexedrone</span> Stimulant and entactogen drug

Mexedrone is a stimulant and an entactogen drug of the cathinone class that has been sold online as a designer drug. It is the alpha-methoxy derivative of Mephedrone.

<span class="mw-page-title-main">Methoxmetamine</span> Chemical compound

Methoxmetamine is a dissociative anesthetic of the arylcyclohexylamine class that is closely related to methoxetamine and methoxyketamine, and has been sold online as a designer drug.

25E-NBOH is a derivative of the phenethylamine derived hallucinogen 2C-E. It was first developed by Martin Hansen at the University of Copenhagen in 2010 as a brain imaging agent, but has subsequently been sold as a designer drug, first being identified in Brazil in 2018 on seized blotter paper, as well as in Slovenia. It acts as a potent serotonin receptor agonist with similar affinity to better-known compounds such as 25I-NBOMe at 5-HT_2A and 5-HT_2C receptors.

2-MAPB is a recreational designer drug with empathogenic effects. As with other related substituted benzofuran derivatives such as 6-APB and 5-MAPB, 2-MAPB is a monoamine releaser with some selectivity for serotonin release, generally similar in pharmacological profile to MDMA but with greater activity as a directly acting agonist of 5-HT₂ receptor subtypes and somewhat greater toxicity. 2-MAPB has been isolated from post-mortem toxicology screens in several drug-related fatal adverse reactions but generally only as a component of combinations of drugs, making it difficult to determine how much it contributed to the deaths. It is illegal in Japan.

References

↑ Koyama T, Izawa Y, Wada H, Makita T, Hashimoto Y, Enomoto M (June 1982). "Toxicological aspects of feprazone, a new nonsteroidal anti-inflammatory drug". Toxicology and Applied Pharmacology. 64 (2): 255–70. doi:10.1016/0041-008X(82)90222-8. PMID 7123554.

This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.

[1] Koyama T, Izawa Y, Wada H, Makita T, Hashimoto Y, Enomoto M (June 1982). "Toxicological aspects of feprazone, a new nonsteroidal anti-inflammatory drug". Toxicology and Applied Pharmacology. 64 (2): 255–70. doi:10.1016/0041-008X(82)90222-8. PMID 7123554.

[1]

v t e Non-steroidal anti-inflammatory drugs (NSAIDs) (primarily M01A and M02A, also N02BA)
pyrazolones / pyrazolidines	Aminophenazone Ampyrone Azapropazone Clofezone Difenamizole Famprofazone Feprazone Kebuzone Metamizole Mofebutazone Morazone Nifenazone Oxyphenbutazone Phenazone Phenylbutazone Propyphenazone Sulfinpyrazone Suxibuzone ^‡
salicylates	Aspirin (acetylsalicylic acid) ^# Aloxiprin Benorylate Carbasalate calcium Diflunisal Dipyrocetyl Ethenzamide Guacetisal Magnesium salicylate Methyl salicylate Salsalate Salicin Salicylamide Salicylic acid (salicylate) Sodium salicylate
acetic acid derivatives and related substances	Aceclofenac Acemetacin Alclofenac Amfenac Bendazac Bromfenac Bufexamac Bumadizone Diclofenac Difenpiramide Etodolac Felbinac Fenclozic acid Fentiazac Indometacin Indometacin farnesil Isoxepac Ketorolac Lonazolac Mofezolac Oxametacin Prodolic acid Proglumetacin Sulindac Tiopinac Tolmetin Zomepirac ^†
oxicams	Ampiroxicam Droxicam Isoxicam Lornoxicam Meloxicam Piroxicam Pivoxicam Tenoxicam
propionic acid derivatives (profens)	Alminoprofen Benoxaprofen ^† Carprofen ^‡ Dexibuprofen Dexketoprofen Fenbufen Fenoprofen Flunoxaprofen Flurbiprofen Ibuprofen ^# Ibuproxam Indoprofen ^† Ketoprofen Loxoprofen Miroprofen Naproxen Oxaprozin Piketoprofen Pirprofen Suprofen Tarenflurbil Tepoxalin ^‡ Tiaprofenic acid Vedaprofen ^‡ Zaltoprofen COX-inhibiting nitric oxide donator : Naproxcinod
n-arylanthranilic acids (fenamates)	Azapropazone Clonixin Etofenamate Floctafenine Flufenamic acid Flunixin Flutiazin Glafenine ^† Meclofenamic acid Mefenamic acid Morniflumate Niflumic acid Tolfenamic acid
COX-2 inhibitors (coxibs)	Apricoxib Celecoxib (+tramadol) Cimicoxib ^‡ Deracoxib ^‡ Etoricoxib Firocoxib ^‡ Lumiracoxib ^† Mavacoxib ^‡ Parecoxib Robenacoxib ^‡ Rofecoxib ^† Valdecoxib ^†
other	Aminopropionitrile Benzydamine Chondroitin sulfate Diacerein Fluproquazone Glucosamine Glycosaminoglycan Hyperforin Nabumetone Nimesulide Oxaceprol Proquazone Superoxide dismutase / orgotein Tenidap
NSAID combinations	Ibuprofen/famotidine Ibuprofen/hydrocodone Ibuprofen/oxycodone Ibuprofen/paracetamol Meloxicam/bupivacaine Naproxen/diphenhydramine Naproxen/esomeprazole
Key: underline indicates initially developed first-in-class compound of specific group; ^# WHO-Essential Medicines; ^† withdrawn drugs; ^‡ veterinary use.
category commons portal